Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia

The increasing incidence of pregnancy complications, particularly gestational diabetes mellitus (GDM) and preeclampsia (PE), is a cause for concern, as they can result in serious health consequences for both mothers and infants. The pathogenesis of these complications is still not fully understood, although it is known that the pathologic placenta plays a crucial role. Studies have shown that PPAR?, a transcription factor involved in glucose and lipid metabolism, may have a critical role in the etiology of these complications. While PPAR? agonists are FDA-approved drugs for Type 2 Diabetes Mellitus, their safety during pregnancy is not yet established. Nevertheless, there is growing evidence for the therapeutic potential of PPAR? in the treatment of PE using mouse models and in cell cultures. This review aims to summarize the current understanding of the mechanism of PPAR? in placental pathophysiology and to explore the possibility of using PPAR? ligands as a treatment option for pregnancy complications. Overall, this topic is of great significance for improving maternal and fetal health outcomes and warrants further investigation.

Automated summary

The increasing incidence of pregnancy complications, such as gestational diabetes mellitus and preeclampsia, is a cause for concern. The pathogenesis of these complications involves the pathological placenta, and the transcription factor PPARγ may have a critical role. While PPARγ agonists show potential in treating preeclampsia, their safety during pregnancy is not yet established.